中文

Home>Biolake

Overview

Updated: 2021-07-14 (chinaopticsvalley.com) Weibo Weixin Qzone Facebook Twitter More

Wuhan National Bio-industry Base, also known as the Biolake, is China's second largest state-level biotech industrial base in view of overall strength, in Wuhan East Lake High-tech Development Zone -- also known as the Optics Valley of China -- located in China's Central Hubei province.

光谷生物城_插图.jpg

[Photo/wehdz.gov.cn]

The construction of the Biolake in the city of Wuhan started in November 2008 and after 11 years of development the bioindustry has become one of the pillar industries of Optics Valley. To date, Optics Valley Biolake has attracted some 3,000 companies to locate there.

At present, Biolake's seven industrial parks have formed an industrial cluster characterized by biomedicines, bio medical engineering, bio agriculture, precision medicine, smart medicines and bio services.

Biolake in OVC is one of China's key new medicine research centers. It is also a national innovative medicine incubator, and national genetic engineering drug public service platform. 

In the biomedicine area, Biolake is considered China's largest medical laser equipment research and production base, national reproductive health industrial base, and national medical equipment manufacturer incubator. To date, Biolake has brought in 187 biomedicine enterprises, and gained more than 450 medical apparatus registration certificates. 

In the bio service area, Biolake has formed a high-end service industrial cluster, with contracted R&D, commissioning manufacture and third-party assessment as its core. At presents, 14 bio service firms in Biolake have obtained national funds. 

Meanwhile, firms dealing with smart medical services also thrive in Biolake, covering wearable devices, remote medical services, health big data integration, health managing consultation, and software and APP development.

Currently, 30 Class I new drugs -- those that have never been marketed in China or overseas – that were developed there have entered the clinical stage.

Officials said that more than 500 Class I and II medical devices, 59 new veterinary drugs and 69 State-approved new varieties of crops developed there have gone on the market -- and 149 products have entered the innovative products catalog of the city of Wuhan. 

光谷生物城 插图新.jpg

[Photo/wehdz.gov.cn]